聚焦海洋医药，全球磷虾油巨头逢时科技荣获国家级专精特新“小巨人”！

Core Insights - The Ministry of Industry and Information Technology has announced the seventh batch of national-level specialized and innovative "little giant" enterprises, with Fengshi Technology being the only company from Shandong in the marine medicine and bioproducts sector to be included, marking a significant recognition of its commitment to the national "Ask the Sea for Medicine" strategy and its focus on marine technology innovation [1][3] Group 1: Company Recognition and Achievements - Fengshi Technology has been recognized as a national-level "little giant" enterprise, achieving this status in just seven years, significantly shorter than the average establishment period of 17.7 years for such companies [3] - The company has accumulated 49 intellectual property rights, including 20 invention patents, and has participated in the formulation of 3 national standards and 9 group standards, positioning itself as a leader in the industry [3] - Fengshi Technology's products have received the ORIVO "5 years 0 defects" certification, with a product repurchase rate of 40%, which is significantly higher than the industry average [5] Group 2: Strategic Collaborations and Innovations - Fengshi Technology has initiated a strategic collaboration with Norway's Aker BioMarine, a leader in the Antarctic krill industry, to develop lipid-lowering drugs, and has published research results on Antarctic krill peptides in collaboration with top domestic universities [8] - The company is focusing on the development of phospholipid-modified drugs for anti-inflammatory and anti-tumor applications, with patents for the preparation processes already accepted by the National Intellectual Property Administration [6][8] - Fengshi Technology aims to leverage the unique properties of krill phospholipids to develop targeted drugs for brain diseases and expand into the field of marine traditional medicine, enhancing the bioavailability and targeted delivery of active ingredients [8]